Home Tools
Log in
Cart

PD-1/PD-L1

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells. Immune checkpoint inhibitors are emerging as a front-line treatment for several types of cancer.
Cat. No. Product name CAS No. Purity Chemical Structure
T35395 Camrelizumab (anti-PD-1) 98%
T36900 PD-1/PD-L1-IN-NP19 2377916-66-8 98%
PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenviron...
T35394 Sintilimab (anti-PD-1) 98%
T12377 PD-1-IN-17 1673560-66-1 98%
PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.
T35396 Spartalizumab (anti-PD-1) 98%
T9616 PD-1/PD-L1-IN-10 2487550-41-2 98%
PD-1/PD-L1-IN-10 is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy.
T12379 PD-1-IN-22 2349372-98-9 98%
PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor(IC50 of 92.3 nM).
TP1076L AUNP-12 acetate 98%
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition t...
T9908 Pembrolizumab 1374853-91-4
Pembrolizumab is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that i...
T9903 Avelumab 1537032-82-8
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity.
T9907 Nivolumab 946414-94-4
Nivolumab anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell ...
T9902 Atezolizumab 1380723-44-3
Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD...
T9359 PDL-1 cpd 10 T9359 97.68%
PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.
T8470 BMS-1001 2113650-03-4 98.89%
BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).
T26859 BMS-8 1675201-90-7 99.06%
BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction.
T5697 BMS-1166 1818314-88-3 99.14%
BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor.
T0844 Sulfamethoxypyridazine 80-35-3 99.3%
Sulfamethoxypyridazine is a sulfanilamide antibacterial agent.
T6S0071 Fraxinellone 28808-62-0 99.35%
1. Fraxinellone significantly reduced weight loss and diarrhea in mice and alleviated the macroscopic and microscopic signs of the disease. 2. Fraxinellone exhib...
T9651 PD-1/PD-L1-IN-9 2628506-54-5 99.37%
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, IC50 = 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells...
T4696 BMS202 hydrochloride (1675203-84-5(free base)) T4696 99.47%
PD-1/PD-L1 inhibitor 2 is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophysical studies demonstrate that BMS202 binds directly to PD-L1. B...
Camrelizumab (anti-PD-1)
T35395
PD-1/PD-L1-IN-NP19
T36900
PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenviron...
Sintilimab (anti-PD-1)
T35394
PD-1-IN-17
T12377
PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.
Spartalizumab (anti-PD-1)
T35396
PD-1/PD-L1-IN-10
T9616
PD-1/PD-L1-IN-10 is an orally active PD-1/PD-L1 inhibitor (IC50 of 2.7 nM) with potent anticancer efficacy.
PD-1-IN-22
T12379
PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor(IC50 of 92.3 nM).
AUNP-12 acetate
TP1076L
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition t...
Pembrolizumab
T9908
Pembrolizumab is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that i...
Avelumab
T9903
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. Avelumab shows potential antibody-dependent cell-mediated cytotoxicity.
Nivolumab
T9907
Nivolumab anti-PD-1) is a genetically engineered fully human immunoglobulin Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell ...
Atezolizumab
T9902
Atezolizumab anti-PD-L1) is a fully humanized IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1 but not the interaction of PD...
PDL-1 cpd 10
T9359
PDL-1 cpd 10 is a novel small molecule PD-L1 inhititor.
BMS-1001
T8470
BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).
BMS-8
T26859
BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction.
BMS-1166
T5697
BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor.
Sulfamethoxypyridazine
T0844
Sulfamethoxypyridazine is a sulfanilamide antibacterial agent.
Fraxinellone
T6S0071
1. Fraxinellone significantly reduced weight loss and diarrhea in mice and alleviated the macroscopic and microscopic signs of the disease. 2. Fraxinellone exhib...
PD-1/PD-L1-IN-9
T9651
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, IC50 = 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells...
BMS202 hydrochloride (1675203-84-5(free base))
T4696
PD-1/PD-L1 inhibitor 2 is a small-molecule PD-1/PD-L1 interaction inhibitor (IC50: 18 nM). Biophysical studies demonstrate that BMS202 binds directly to PD-L1. B...
1 2